1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Monoclonal Antibodies Partnering Terms and Agreements - CP21131 -Feb2015v5

The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?



The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since January 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive list and detailed review of monoclonal antibody partnering deals signed and announced since January 2010, by specific technology type. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by the monoclonal antibody partnering company A-Z, deal type, stage of development and therapy type deals. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Report scope

Monoclonal Antibodies Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Monoclonal Antibodies Partnering Terms & Agreements includes:

Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010
Analysis of monoclonal antibodies deal structure
Access to headline, upfront, milestone and royalty data
Access to over 500 monoclonal antibodies deal records
The leading monoclonal antibodies deals by value since 2010
Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010

In Monoclonal AntibodiesPartnering Terms & Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Monoclonal Antibodies Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 500 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Monoclonal Antibodies Partnering Terms & Agreements provides the reader with the following key benefits:

In-depth understanding of monoclonal antibodies deal trends since 2010
Access to headline, upfront, milestone and royalty data
Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
Comprehensive access to over 500 actual monoclonal antibodies deals entered into by the world’s biopharma companies, together with real world clause examples
Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
Identify leading monoclonal antibodies deals by value since 2010
Identify the most active r monoclonal antibodies dealmakers since 2010
Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Monoclonal Antibodies Partnering Terms and Agreements - CP21131 -Feb2015v5
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Big pharma monoclonal antibody dealmaking activity
2.4. Big biotech monoclonal antibody dealmaking activity
2.5. Most active in monoclonal antibody partnering
2.6. Monoclonal antibody partnering by deal type
2.7. Monoclonal antibody partnering by disease type
2.8. Monoclonal antibody partnering by specific technology type
2.9 Average deal terms for monoclonal antibody
2.9.1 Monoclonal antibody headline values
2.9.2 Monoclonal antibody upfront payments
2.9.3 Monoclonal antibody milestone payments
2.9.4 Monoclonal antibody royalty rates
2.10. The anatomy of monoclonal antibody partnering
2.10.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.10.b. Case study 2: Case study 2: Amgen- AstraZeneca: April 2, 2012

Chapter 3 - Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 - Big pharma monoclonal antibody deals
4.1. Introduction
4.2. How to use big pharma monoclonal antibody partnering deals
4.3. Big pharma monoclonal antibody partnering company profiles

Chapter 5 - Big biotech monoclonal antibodies deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech monoclonal antibody partnering company profiles

Chapter 6 - Monoclonal antibody contracts dealmaking directory
6.1. Introduction
6.2. Monoclonal antibody contracts dealmaking directory by company A-Z
6.3. Monoclonal antibody contracts dealmaking directory by deal type
6.4. Monoclonal antibody contracts dealmaking directory by stage of development
6.5. Monoclonal antibody contracts dealmaking directory by therapy indication

Chapter 7 - Monoclonal antibody deals by individual technology type
Monoclonal antibodies

Chapter 8 - Monoclonal antibody partnering resource center
8.1. Online monoclonal antibody partnering
8.2. Monoclonal antibody partnering events
8.3. Further reading on monoclonal antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form - Technology reports
Order Form - Upgrades to subscription access products


See accompanying volume for:
Appendices
Introduction
Appendix 1 - Directory of monoclonal antibody deals by company A-Z 2010-2015
Appendix 2 - Directory of monoclonal antibody deals by stage of development 2010-2015
Appendix 3 - Directory of monoclonal antibody deals by deal type 2010-2015
Appendix 4 - Directory of monoclonal antibody deals by therapy area 2010-2015
Appendix 5 - Monoclonal antibody partnering resource center
Online monoclonal antibody partnering
Monoclonal antibody partnering events
Further reading on monoclonal antibody dealmaking

Table of figures

Figure 1: Monoclonal antibody partnering since 2010
Figure 2: Big pharma - top 50 - monoclonal antibody deals 2010 to 2015
Figure 3: Big pharma monoclonal antibody deal frequency - 2010 to 2015
Figure 4: Big biotech -monoclonal antibody deals 2010 to 2015
Figure 5: Big biotech monoclonal antibody deal frequency - 2010 to 2015
Figure 6: Active monoclonal antibody dealmaking activity- 2010 to 2015
Figure 7: Monoclonal antibody partnering by deal type since 2010
Figure 8: Monoclonal antibody partnering by disease type since 2010
Figure 9: Monoclonal antibody partnering by oncology target since 2010
Figure 10: Monoclonal antibody partnering by technology type since 2010
Figure 11: Monoclonal antibody deals with a headline value
Figure 12: Monoclonal antibody deals with an upfront value
Figure 13: Monoclonal antibody deals with a milestone value
Figure 14: Monoclonal antibody deals with royalty rates
Figure 15: Components of the typical monoclonal antibody deal structure
Figure 16: Top monoclonal antibody deals by value since 2010
Figure 17: Online partnering resources
Figure 18: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.